NCT05607953View on ClinicalTrials.gov

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

October 31, 2027

Conditions
Locally Advanced Pancreatic Adenocarcinoma
Interventions
DRUG

SD-101

SD-101 doses are administered via PRVI using the PEDD method of administration

BIOLOGICAL

anti-PD-1

In the Phase 1b, anti-PD-1 will be administered together with SD-101

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

TriSalus Life Sciences, Inc.

INDUSTRY